Premium
Urine metabolomics and proteomics for bladder cancer prediction by LC/MS based strategy
Author(s) -
Tang Xiaoyue,
Guo Zhengguang,
Sun Haidan,
Liu Xiaoyan,
Liu Xiang,
Li Jing,
Lian Xiaoxiao,
Zheng Shuxin
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.01764
Subject(s) - urothelium , urine , bladder cancer , medicine , cystoscopy , proteomics , urology , metabolomics , metabolite , oncology , cancer , urinary bladder , bioinformatics , urinary system , biology , biochemistry , gene
Early diagnosis and life‐long surveillance are clinically important to improve the long‐term survival of bladder cancer (BCa) patients. Cystoscopy is considered the gold standard for the clinical diagnosis of human BCa. However, it is expensive and invasive. The objective of this study was to discover novel biomarkers to distinguish BCa from healthy controls, urothelium carcinoma and benign bladder lesions by LC‐MS based metabolomics and proteomics. We also tried to differentiate high‐grade and low‐grade BCa. A total of 234 subjects were enrolled, including 80 healthy adults, 22 benign patients, 26 urothelium carcinoma patients and 106 BCa patients (63 high‐grade BCa, 43 low‐grade BCa). The results showed that both urine metabolites and urine proteins could distinguish the BCa group from the healthy group, urothelium carcinoma group and benign bladder lesions group. And the combination of metabolites and proteins could achieve higher accuracy. Similarly, BCa clinical stages (high‐ vs. low‐grade BCa) could be better separated with a panel consisting of metabolites and proteins than either the metabolite panel or the protein panel alone. In conclusion, this study showed that urine proteomic and metabolic profiling were able to assist in the detection of BCa and grading distinguish. Support or Funding Information National Basic Research Program of China (No. 2013CB530805, 2014CBA02005)